Frank S. Wu

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

D. Planchard, P. Jänne, M. Ahn, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.

D. Schadendorf, R. Dummer, M. Casey, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.